Sight Sciences, Inc. Update: A Major Legal Win

Sight Sciences (SGHT) recently made the strategic decision to sell its TearCare dry eye business to focus entirely on its surgical glaucoma tools. Now, the company has received a significant boost from a U.S. District Court that strengthens its position in the market.

1. What happened?

On March 27, 2026, a federal court upheld a jury’s verdict against Alcon, a global eye care giant. The court ruled that Alcon willfully used Sight Sciences’ patented technology without permission. Specifically, the court found that Alcon’s "Hydrus" device infringed on three patents protecting the OMNI Surgical System.

2. What does this mean for the company’s bank account?

The court awarded Sight Sciences $34 million for past sales, consisting of $5.5 million in lost profits and $28.5 million in royalties.

Additionally, the court granted Sight Sciences a 10% royalty on all future U.S. sales of the Alcon Hydrus device until the patents expire on November 10, 2028. For context, Sight Sciences reported $81 million in total revenue for 2024. This new royalty stream represents high-margin income that doesn't require issuing new shares, which protects your existing ownership percentage.

Note: The company will pay a $5.4 million success fee to its legal team, which is a standard one-time cost for a victory of this scale.

3. Why does this matter?

This win validates the company’s new, focused strategy. By exiting the dry eye market, Sight Sciences is betting everything on its OMNI and SION glaucoma devices. This legal victory acts as a defensive wall, proving their technology is legally protected against a major competitor. It effectively turns a competitor's market success into a recurring revenue stream that helps fund Sight Sciences’ own growth.

4. Is the money guaranteed?

Not yet. There are two main hurdles to keep in mind:

• The Appeal: Alcon will likely appeal the decision. This process usually takes 12 to 18 months, and the $34 million payment is on hold until the legal process concludes.
• Patent Challenges: Alcon is also challenging the validity of the patents themselves. If a specialized patent board decides the patents shouldn't have been granted, the award and future royalties could be at risk.

5. What should investors know?

• Validation: The ruling supports the idea that Sight Sciences has top-tier technology in the glaucoma surgery market.
• Patience is required: View this as a long-term asset rather than immediate cash. The $34 million will likely stay in legal limbo until the appeals process finishes.
• Concentration Risk: With the dry eye business gone, the company’s value depends entirely on the OMNI and SION systems. Any regulatory issues or changes in insurance coverage for these specific devices will now have a much larger impact on the stock price.

6. What happens next?

The court will finalize the exact damages, including interest, in the coming months. Keep an eye on the company’s quarterly reports for updates on legal costs and the appeals timeline. While this is a positive development, the actual cash remains tied up in the court system for now.

---

Investor Takeaway: This ruling is a strong signal of the value of Sight Sciences' intellectual property, but it is not an immediate financial windfall. When evaluating this stock, focus on the company's ability to grow its OMNI and SION sales, as these are now the primary drivers of the business. Treat the legal award as a potential "bonus" that may take over a year to materialize.

Disclaimer: I am an AI, not a financial advisor. This summary is for informational purposes only and should not be considered financial advice. Always do your own research before making investment decisions.